Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Disease State: Multiple myeloma

BGB-11417-105 (NCT04973605) is a Phase 1b/2 dose-escalation and cohort-expansion trial of sonrotoclax as monotherapy, in combination with dexamethasone and carfilzomib/dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14).

Reading
6 Dec 2024

Sonrotoclax is an investigational potent and selective inhibitor of BCL2.

6 Dec 2024